ANUH PHARMA LIMITED
Latest filings
Next results: Fri, 30 Oct · Financial Results- Board to approve September 2026 quarterly and half-year results · Results
- Anuh Pharma takes possession of Vanquest Pharma manufacturing facility · Capex & Operations
- Anuh Pharma to acquire API manufacturing facility from Vanquest Pharma for Rs 72.9 Cr · Strategic Transactions
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures active pharmaceutical ingredients (APIs), also known as bulk drugs, which are the chemical compounds used by other drug makers to produce finished medicines. The product slate is expanding into regulated-market molecules, with new additions cited as Vonoprazon Fumarate, Pretomanid, and Edoxaban Tosylate. Revenue comes from two streams: domestic sales (around 54% of revenue) and exports (around 46%), with Africa (33% of exports), Asia (35%), and Europe (24%) as the named export geographies. The manufacturing base produced 1,733 metric tonnes in FY26 (up about 25% year-on-year), running against installed capacity of 2,400 MTPA, and the facilities cleared USFDA and EU GMP inspections with zero 483 observations. Costs are dominated by raw materials at 66.1% of revenue, with employee cost at 3.4% and other operating expenses at 10.9%. Depreciation is 1.5% and capex 1.0% of revenue, indicating a relatively capital-light profile. EBITDA margin compressed to 8.56% in FY26, with net profit of Rs. 41.05 crore on revenue of Rs. 771.66 crore.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from ANUH PHARMA LIMITED's filed financials and exchange disclosures
What does ANUH PHARMA LIMITED do?
ANUH PHARMA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol ANUHPHR.
Is ANUH PHARMA LIMITED profitable?
Yes. Over the trailing twelve months ANUH PHARMA LIMITED reported a net profit of ₹52 Cr on revenue of ₹965 Cr.
Does ANUH PHARMA LIMITED pay a dividend?
Yes. The dividend yield is 1.87% at the current price. It paid out 37% of its profit as dividend in FY26.
Is ANUH PHARMA LIMITED debt-free?
Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹8.06 Cr of cash.
Is ANUH PHARMA LIMITED expensive compared with its peers?
On trailing P/E, ANUH PHARMA LIMITED ranks 34 of 158 in Pharmaceuticals — cheaper than 79% of them, against an industry median of 30.2×. This is a position, not a valuation judgement.
How much does the ANUH PHARMA LIMITED share price move in a day?
On a typical session ANUH PHARMA LIMITED moves 1.15% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
When are ANUH PHARMA LIMITED's next results?
Financial Results on Fri, 30 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track ANUH PHARMA LIMITED's announcements?
Every NSE and BSE filing by ANUH PHARMA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.